加兰他敏治疗阿尔茨海默病疗效的meta分析

发布时间：2018-09-01 08:25

【摘要】：目的:采用循证医学的方法评价加兰他敏治疗阿尔茨海默病(Alzheimer’s disease,AD)效果。方法:检索国内外发表的有关加兰他敏治疗阿尔茨海默病的随机对照试验(RCTs)文献,采用Meta分析方法,利用RevMan5.0软件评价加兰他敏的疗效。计算合并均数差(MD)和相对危险度(RR)值,95%置信区间(CI),及不良反应发生率。结果:最终纳入11篇RCTs。分析结果显示:在认知能力方面,加兰他敏对AD的MMSE量表评分在治疗后提高(MD=2.04,95%CI:0.77,3.31),在基线分数基础上,ADAS-Cog积分评分下降,有积极作用(MD=-3.20,95%CI:-3.60,-2.80);在生活能力上,加兰他敏对AD的ADL量表评分无明显影响(MD=0.25,95%CI:-1.10,1.60),在DAD量表评分上经加兰他敏治疗后有所提高(MD=4.06,95%CI:3.83,4.28);在行为能力上,加兰他敏对AD的NPI量表评分下降(MD=-1.36,95%CI:-2.21,-0.52);AD患者经加兰他敏治疗对CIBIC-plus分数改变有着积极的作用。不良反应呕吐发生率最高,但对腹泻无明显影响作用。结论:加兰他敏对AD患者在认知、生活能力、行为能力和CIBIC-plus分数改变有一定治疗效果,但仍需更充分的证据。
[Abstract]:Objective: to evaluate the efficacy of galantamine in the treatment of Alzheimer's disease (Alzheimer's disease,AD) by evidence-based medicine. Methods: the literature published at home and abroad on the randomized controlled trial (RCTs) of galantamine in the treatment of Alzheimer's disease was searched. Meta analysis was used to evaluate the efficacy of galantamine by RevMan5.0 software. The combined mean difference (MD) and relative risk (RR) of 95% confidence interval (CI),) and the incidence of adverse reactions were calculated. Results: 11 RCTs. articles were eventually included The results showed that: in cognitive ability, Galantamine's MMSE score of AD increased after treatment (MD=2.04,95%CI:0.77,3.31), and the score of ADAS-Cog decreased on the base of baseline score (MD=-3.20,95%CI:-3.60,-2.80), and had a positive effect (MD=-3.20,95%CI:-3.60,-2.80) on ability of life. Galantamine had no significant effect on the ADL score of AD (MD=0.25,95%CI:-1.10,1.60), but it was improved (MD=4.06,95%CI:3.83,4.28) in the DAD score after treatment with Galantamine, and the behavioral ability was increased after treatment. Galantamine had a positive effect on the change of CIBIC-plus score in AD patients with NPI score decline (MD=-1.36,95%CI:-2.21,-0.52) of AD. The incidence of vomiting was the highest, but had no effect on diarrhea. Conclusion: Galantamine has some therapeutic effects on the changes of cognition, life ability, behavioral ability and CIBIC-plus score in patients with AD, but more sufficient evidence is needed.
【作者单位】：重庆医科大学公共卫生与管理学院流行病与卫生统计;
【基金】：重庆市科技计划项目(编号cstc2011jjA10021)
【分类号】：R749.16

【参考文献】